Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity

Summary Over the past 30 years, there has been a dramatic rise in global obesity prevalence, resulting in significant economic and social consequences. Attempts to develop pharmacological agents to treat obesity have met with many obstacles including the lack of long‐term effectiveness and the potential for adverse effects. Historically, there have been limited treatment options for overweight and obesity; however, since 2012, a number of new drugs have become available. A number of peptides produced in the gut act as key mediators of the gut–brain axis, which is involved in appetite regulation. This review discusses the role of the gut–brain axis in appetite regulation with special focus on glucagon‐like peptide‐1. Liraglutide 3.0 mg, a glucagon‐like peptide‐1 receptor agonist that targets this pathway, is now approved for the treatment of obesity and overweight (body mass index ≥27 kg/m 2 ) with comorbidities such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea. In addition, other glucagon‐like peptide‐1 receptor agonists offer promise for obesity management in the future. This review examines how glucagon‐like peptide‐1 receptor agonists promote weight loss and summarizes the clinical data on weight loss with glucagon‐like peptide‐1 receptor agonists.